BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) interview with CEO, Chaim Lebovits, discussing the company’s advancements in developing stem cell therapies to treat neurodegenerative diseases. The company’s pipeline includes a lead indication for ALS- Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease), now in Phase III FDA clinical trials.
BrainStorm’s technology is based on using the patients own stem cells, extracted from bone marrow, which are then grown in proprietary conditions, converting them into “biological factories” secreting a variety of neurotrophic factors (NTFs). These stem cells are then re-injected into the patient. NTFs are growth factors known to support the survival of neurons in a variety of conditions, and in animal models of many neurodegenerative diseases.